Novo Nordisk Receives FDA Approval for 25mg Oral Wegovy Weight Loss Pill
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Globenewswire
- FDA Approval Milestone: On December 22, 2025, Novo Nordisk announced that its 25mg oral Wegovy weight loss pill received FDA approval, marking a significant breakthrough as the first oral GLP-1 therapy for chronic weight management, enhancing the company's position in the weight loss medication market.
- Market Launch Plan: Novo Nordisk plans a full U.S. launch in early January 2026, expected to meet the rising demand for weight loss solutions, particularly as consumer interest in weight loss medications typically spikes around the New Year.
- Clinical Trial Results: The OASIS 4 trial demonstrated an average weight loss of 13-14% with the oral Wegovy, with some participants achieving up to 16.6% weight reduction, providing robust clinical support for the company's competitive stance in the weight loss market.
- Insurance Coverage Challenges: Despite the FDA approval of oral Wegovy, insurance coverage policies vary widely, requiring patients to bear costs themselves, which may impact the drug's market acceptance and sales potential.
NVO
$52.4+Infinity%1D
Analyst Views on NVO
Wall Street analysts forecast NVO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NVO is 57.37 USD with a low forecast of 47.00 USD and a high forecast of 70.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
4 Buy
2 Hold
1 Sell
Moderate Buy
Current: 52.560
Low
47.00
Averages
57.37
High
70.00
Current: 52.560
Low
47.00
Averages
57.37
High
70.00
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
